Disclosed is the monohydrate of the compound 4-[4-({ [4-chloro-3-(trifluoromethyl)phenyl]carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide (also known as 4-{ 4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy} -pyridine-2-carboxylic acid methylamide). Further disclosed is a pharmaceutical composition which comprising mainly the compound as defined above, no significant fractions of another form of the compound and one or more inert, nontoxic, pharmaceutically suitable excipients for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.
